Tratamento da coccidioidomicose

Translated title of the contribution: The treatment of coccidioidomycosis

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Therapy of coccidioidomycosis continues to evolve. For primary pulmonary disease, antifungal therapy is frequently not required while prolonged courses of antifungals are generally needed for those in whom extrathoracic disseminated has occurred. Intravenous amphotericin B should be reserved for those with severe disease. Oral triazole antifungals have had a great impact on the management of coccidioidomycosis. Both fluconazole and itraconazole at 400 mg daily have been effective for various forms of coccidioidomycosis, including meningitis, although relapse after therapy is discontinued is a problem. Individuals with suppressed cellular immunity are at increased risk for symptomatic coccidioidomycosis and they include those with HIV infection, those on immunosuppressive medications, and those who have received a solid organ transplant. Pregnant women and African-American men have been identified as two other groups who are at an increased risk for symptomatic and severe infection.

Original languageUndefined/Unknown
Pages (from-to)51-56
Number of pages6
JournalRevista do Instituto de Medicina Tropical de Sao Paulo
Volume57
DOIs
StatePublished - Sep 1 2015

Fingerprint

Coccidioidomycosis
Triazoles
Itraconazole
Fluconazole
Amphotericin B
Therapeutics
Immunosuppressive Agents
Meningitis
Cellular Immunity
African Americans
Lung Diseases
HIV Infections
Pregnant Women
Transplants
Recurrence
Infection

Keywords

  • Antifungal therapy
  • Coccidioidomycosis
  • Fungi
  • Mycotic infections

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

Tratamento da coccidioidomicose. / Ampel, Neil M.

In: Revista do Instituto de Medicina Tropical de Sao Paulo, Vol. 57, 01.09.2015, p. 51-56.

Research output: Contribution to journalArticle

@article{468010b676be4ee1954f9a8567ea6bc2,
title = "Tratamento da coccidioidomicose",
abstract = "Therapy of coccidioidomycosis continues to evolve. For primary pulmonary disease, antifungal therapy is frequently not required while prolonged courses of antifungals are generally needed for those in whom extrathoracic disseminated has occurred. Intravenous amphotericin B should be reserved for those with severe disease. Oral triazole antifungals have had a great impact on the management of coccidioidomycosis. Both fluconazole and itraconazole at 400 mg daily have been effective for various forms of coccidioidomycosis, including meningitis, although relapse after therapy is discontinued is a problem. Individuals with suppressed cellular immunity are at increased risk for symptomatic coccidioidomycosis and they include those with HIV infection, those on immunosuppressive medications, and those who have received a solid organ transplant. Pregnant women and African-American men have been identified as two other groups who are at an increased risk for symptomatic and severe infection.",
keywords = "Antifungal therapy, Coccidioidomycosis, Fungi, Mycotic infections",
author = "Ampel, {Neil M.}",
year = "2015",
month = "9",
day = "1",
doi = "10.1590/S0036-46652015000700010",
language = "Undefined/Unknown",
volume = "57",
pages = "51--56",
journal = "Revista do Instituto de Medicina Tropical de Sao Paulo",
issn = "0036-4665",
publisher = "Instituto de Medicina Tropical de Sao Paulo",

}

TY - JOUR

T1 - Tratamento da coccidioidomicose

AU - Ampel, Neil M.

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Therapy of coccidioidomycosis continues to evolve. For primary pulmonary disease, antifungal therapy is frequently not required while prolonged courses of antifungals are generally needed for those in whom extrathoracic disseminated has occurred. Intravenous amphotericin B should be reserved for those with severe disease. Oral triazole antifungals have had a great impact on the management of coccidioidomycosis. Both fluconazole and itraconazole at 400 mg daily have been effective for various forms of coccidioidomycosis, including meningitis, although relapse after therapy is discontinued is a problem. Individuals with suppressed cellular immunity are at increased risk for symptomatic coccidioidomycosis and they include those with HIV infection, those on immunosuppressive medications, and those who have received a solid organ transplant. Pregnant women and African-American men have been identified as two other groups who are at an increased risk for symptomatic and severe infection.

AB - Therapy of coccidioidomycosis continues to evolve. For primary pulmonary disease, antifungal therapy is frequently not required while prolonged courses of antifungals are generally needed for those in whom extrathoracic disseminated has occurred. Intravenous amphotericin B should be reserved for those with severe disease. Oral triazole antifungals have had a great impact on the management of coccidioidomycosis. Both fluconazole and itraconazole at 400 mg daily have been effective for various forms of coccidioidomycosis, including meningitis, although relapse after therapy is discontinued is a problem. Individuals with suppressed cellular immunity are at increased risk for symptomatic coccidioidomycosis and they include those with HIV infection, those on immunosuppressive medications, and those who have received a solid organ transplant. Pregnant women and African-American men have been identified as two other groups who are at an increased risk for symptomatic and severe infection.

KW - Antifungal therapy

KW - Coccidioidomycosis

KW - Fungi

KW - Mycotic infections

UR - http://www.scopus.com/inward/record.url?scp=84944449365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944449365&partnerID=8YFLogxK

U2 - 10.1590/S0036-46652015000700010

DO - 10.1590/S0036-46652015000700010

M3 - Article

C2 - 26465370

AN - SCOPUS:84944449365

VL - 57

SP - 51

EP - 56

JO - Revista do Instituto de Medicina Tropical de Sao Paulo

JF - Revista do Instituto de Medicina Tropical de Sao Paulo

SN - 0036-4665

ER -